CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Shionogi to pay $2B for IntraBio, a commercial rare disease biotech

AqneursaPositive
AI Analysis

Summary

Shionogi is acquiring IntraBio, a commercial biotech focused on rare diseases, for $2 billion upfront, adding the oral treatment Aqneursa to its portfolio.

Importance:7/10
Sentiment:
0.60
M&ARare DiseaseAcquisitionCommercial Biotech
Related Companies

Read the original article

Published by Endpoints News on October 5, 2026 2:19 PM

Read Original